Last reviewed · How we verify
dose dense ABVD
At a glance
| Generic name | dose dense ABVD |
|---|---|
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- FIL Study on ABVD DD-DI as Upfront Therapy in HL. (PHASE3)
- Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dose dense ABVD CI brief — competitive landscape report
- dose dense ABVD updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI